NCT04234048View on ClinicalTrials.gov

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

May 1, 2027

Conditions
T-cell LymphomaCutaneous/Peripheral T-Cell LymphomaPeripheral T-cell LymphomaPeripheral T-Cell Lymphoma, Not ClassifiedPrimary Cutaneous T-cell LymphomaCutaneous T-Cell Lymphoma, UnspecifiedCutaneous T-cell LymphomaFollicular T-Cell LymphomaAngioimmunoblastic T-cell LymphomaSézary's DiseaseMycosis Fungoides
Interventions
DRUG

Fenretinide

"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"

Trial Locations (10)

10032

RECRUITING

Columbia University, New York

15219

RECRUITING

University of Pittsburgh Medical Center (UPMC), Pittsburgh

48109

RECRUITING

University of Michigan, Ann Arbor

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute Wayne State University, Detroit

60611

RECRUITING

Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

85259

RECRUITING

Mayo Clinic Arizona, Scottsdale

90007

RECRUITING

University of Southern California, Los Angeles

91010

RECRUITING

City of Hope Medical Foundation, Duarte

All Listed Sponsors
lead

SciTech Development, Inc.

INDUSTRY